Stock Movers: Gemini Rises, Oracle Slumps, Eli Lilly's Weight-Loss Drug

Gemini Space Station's Regulatory Milestone

• 🚀 Gemini Space Station (GEMI) shares increased by 5.5% following the announcement of a Designated Contract Market license from the CFTC.
• 💡 This license permits Gemini to offer prediction markets within the US, allowing customers to trade event contracts.
• 📈 Analysts are optimistic that this development could lead to an increased client base and transaction volume, despite the stock being down nearly 60% from its IPO.

Oracle's Cloud Sales Concerns

• 📉 Oracle (ORCL) shares dropped 15% due to a disappointing third-quarter cloud revenue forecast that fell below analyst expectations.
• ⚠️ Investors are concerned that Oracle's substantial backlog of orders may not translate into profitable revenue streams, especially with increasing competition from companies like Alphabet's Google.
• 📊 The company's forecast also comes alongside a significant increase in fiscal year capital expenditures and a large cash outflow.

Eli Lilly's Promising Obesity Shot

• ✨ Eli Lilly (LLY) shares saw an early jump of nearly 4% on positive results from its experimental obesity drug, retatrutide.
• 🎯 Patients using the highest dose of the drug lost over 23% of their body weight in 68 weeks, suggesting it could be a best-in-class weight-loss medication.
• 🔬 Further developments are anticipated in 2026, but the initial results are a highly positive indicator for the stock.